Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
ObjectiveTo examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed golimumab or adalimumab.DesignThis was a retrospective chart review study in adult patients diagnosed with UC using data from 16 Natio...
Saved in:
| Published in | BMJ open gastroenterology Vol. 7; no. 1; p. e000476 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BMJ Publishing Group Ltd
16.11.2020
BMJ Publishing Group LTD BMJ Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2054-4774 2054-4774 |
| DOI | 10.1136/bmjgast-2020-000476 |
Cover
| Abstract | ObjectiveTo examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed golimumab or adalimumab.DesignThis was a retrospective chart review study in adult patients diagnosed with UC using data from 16 National Health Service sites in the UK. Patient records were included in the study if they had initiated first or second-line adalimumab or golimumab between 1 March 2016 and 30 September 2017 (index date). Subjects were required for ≥6 months post treatment initiation. Demographics, clinical characteristics, treatment-related data and colectomy data were extracted over a follow-up period of 6–12 months. Treatment persistence rate was the primary outcome. Colectomy-free survival and treatment switching were secondary outcomes. Outcomes were compared between treatments using χ2 tests and Fisher’s exact test for categorical variables. The t-tests were used for continuous variables. Time-to-event variables were evaluated using Kaplan-Meier curves and log-rank tests.ResultsThe study included a total of 183 patients (96 (52.5%) prescribed adalimumab; 87 (47.5%) golimumab), and patients were mostly first line (79.8%). Demographic and clinical characteristics were generally similar between treatment groups. Persistence rates within 12 months were 64.6% for adalimumab and 64.4% for golimumab (p=0.681). Overall, 20.2% switched to other therapy within 1 year, with 8.2% golimumab and 12.0% adalimumab switching to another biologic. Of patients prescribed adalimumab, 14.6% had ≥1 dose change, mainly dose escalations. In the 12 months post treatment initiation, 8.2% of patients underwent colectomy, with no significant difference in colectomy-free survival by treatment, p=0.73.ConclusionThis study provides evidence of clinical outcomes and real-world persistence for adalimumab and golimumab in UC. The persistence rates of both therapies were above 64.0% at 12 months following treatment initiation. In addition, the 1-year colectomy-free survival was relatively similar between the two treatments. |
|---|---|
| AbstractList | Objective To examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed golimumab or adalimumab.Design This was a retrospective chart review study in adult patients diagnosed with UC using data from 16 National Health Service sites in the UK. Patient records were included in the study if they had initiated first or second-line adalimumab or golimumab between 1 March 2016 and 30 September 2017 (index date). Subjects were required for ≥6 months post treatment initiation. Demographics, clinical characteristics, treatment-related data and colectomy data were extracted over a follow-up period of 6–12 months. Treatment persistence rate was the primary outcome. Colectomy-free survival and treatment switching were secondary outcomes. Outcomes were compared between treatments using χ2 tests and Fisher’s exact test for categorical variables. The t-tests were used for continuous variables. Time-to-event variables were evaluated using Kaplan-Meier curves and log-rank tests.Results The study included a total of 183 patients (96 (52.5%) prescribed adalimumab; 87 (47.5%) golimumab), and patients were mostly first line (79.8%). Demographic and clinical characteristics were generally similar between treatment groups. Persistence rates within 12 months were 64.6% for adalimumab and 64.4% for golimumab (p=0.681). Overall, 20.2% switched to other therapy within 1 year, with 8.2% golimumab and 12.0% adalimumab switching to another biologic. Of patients prescribed adalimumab, 14.6% had ≥1 dose change, mainly dose escalations. In the 12 months post treatment initiation, 8.2% of patients underwent colectomy, with no significant difference in colectomy-free survival by treatment, p=0.73.Conclusion This study provides evidence of clinical outcomes and real-world persistence for adalimumab and golimumab in UC. The persistence rates of both therapies were above 64.0% at 12 months following treatment initiation. In addition, the 1-year colectomy-free survival was relatively similar between the two treatments. To examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed golimumab or adalimumab. This was a retrospective chart review study in adult patients diagnosed with UC using data from 16 National Health Service sites in the UK. Patient records were included in the study if they had initiated first or second-line adalimumab or golimumab between 1 March 2016 and 30 September 2017 (index date). Subjects were required for ≥6 months post treatment initiation. Demographics, clinical characteristics, treatment-related data and colectomy data were extracted over a follow-up period of 6-12 months. Treatment persistence rate was the primary outcome. Colectomy-free survival and treatment switching were secondary outcomes. Outcomes were compared between treatments using χ tests and Fisher's exact test for categorical variables. The t-tests were used for continuous variables. Time-to-event variables were evaluated using Kaplan-Meier curves and log-rank tests. The study included a total of 183 patients (96 (52.5%) prescribed adalimumab; 87 (47.5%) golimumab), and patients were mostly first line (79.8%). Demographic and clinical characteristics were generally similar between treatment groups. Persistence rates within 12 months were 64.6% for adalimumab and 64.4% for golimumab (p=0.681). Overall, 20.2% switched to other therapy within 1 year, with 8.2% golimumab and 12.0% adalimumab switching to another biologic. Of patients prescribed adalimumab, 14.6% had ≥1 dose change, mainly dose escalations. In the 12 months post treatment initiation, 8.2% of patients underwent colectomy, with no significant difference in colectomy-free survival by treatment, p=0.73. This study provides evidence of clinical outcomes and real-world persistence for adalimumab and golimumab in UC. The persistence rates of both therapies were above 64.0% at 12 months following treatment initiation. In addition, the 1-year colectomy-free survival was relatively similar between the two treatments. ObjectiveTo examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed golimumab or adalimumab.DesignThis was a retrospective chart review study in adult patients diagnosed with UC using data from 16 National Health Service sites in the UK. Patient records were included in the study if they had initiated first or second-line adalimumab or golimumab between 1 March 2016 and 30 September 2017 (index date). Subjects were required for ≥6 months post treatment initiation. Demographics, clinical characteristics, treatment-related data and colectomy data were extracted over a follow-up period of 6–12 months. Treatment persistence rate was the primary outcome. Colectomy-free survival and treatment switching were secondary outcomes. Outcomes were compared between treatments using χ2 tests and Fisher’s exact test for categorical variables. The t-tests were used for continuous variables. Time-to-event variables were evaluated using Kaplan-Meier curves and log-rank tests.ResultsThe study included a total of 183 patients (96 (52.5%) prescribed adalimumab; 87 (47.5%) golimumab), and patients were mostly first line (79.8%). Demographic and clinical characteristics were generally similar between treatment groups. Persistence rates within 12 months were 64.6% for adalimumab and 64.4% for golimumab (p=0.681). Overall, 20.2% switched to other therapy within 1 year, with 8.2% golimumab and 12.0% adalimumab switching to another biologic. Of patients prescribed adalimumab, 14.6% had ≥1 dose change, mainly dose escalations. In the 12 months post treatment initiation, 8.2% of patients underwent colectomy, with no significant difference in colectomy-free survival by treatment, p=0.73.ConclusionThis study provides evidence of clinical outcomes and real-world persistence for adalimumab and golimumab in UC. The persistence rates of both therapies were above 64.0% at 12 months following treatment initiation. In addition, the 1-year colectomy-free survival was relatively similar between the two treatments. To examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed golimumab or adalimumab.OBJECTIVETo examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed golimumab or adalimumab.This was a retrospective chart review study in adult patients diagnosed with UC using data from 16 National Health Service sites in the UK. Patient records were included in the study if they had initiated first or second-line adalimumab or golimumab between 1 March 2016 and 30 September 2017 (index date). Subjects were required for ≥6 months post treatment initiation. Demographics, clinical characteristics, treatment-related data and colectomy data were extracted over a follow-up period of 6-12 months. Treatment persistence rate was the primary outcome. Colectomy-free survival and treatment switching were secondary outcomes. Outcomes were compared between treatments using χ2 tests and Fisher's exact test for categorical variables. The t-tests were used for continuous variables. Time-to-event variables were evaluated using Kaplan-Meier curves and log-rank tests.DESIGNThis was a retrospective chart review study in adult patients diagnosed with UC using data from 16 National Health Service sites in the UK. Patient records were included in the study if they had initiated first or second-line adalimumab or golimumab between 1 March 2016 and 30 September 2017 (index date). Subjects were required for ≥6 months post treatment initiation. Demographics, clinical characteristics, treatment-related data and colectomy data were extracted over a follow-up period of 6-12 months. Treatment persistence rate was the primary outcome. Colectomy-free survival and treatment switching were secondary outcomes. Outcomes were compared between treatments using χ2 tests and Fisher's exact test for categorical variables. The t-tests were used for continuous variables. Time-to-event variables were evaluated using Kaplan-Meier curves and log-rank tests.The study included a total of 183 patients (96 (52.5%) prescribed adalimumab; 87 (47.5%) golimumab), and patients were mostly first line (79.8%). Demographic and clinical characteristics were generally similar between treatment groups. Persistence rates within 12 months were 64.6% for adalimumab and 64.4% for golimumab (p=0.681). Overall, 20.2% switched to other therapy within 1 year, with 8.2% golimumab and 12.0% adalimumab switching to another biologic. Of patients prescribed adalimumab, 14.6% had ≥1 dose change, mainly dose escalations. In the 12 months post treatment initiation, 8.2% of patients underwent colectomy, with no significant difference in colectomy-free survival by treatment, p=0.73.RESULTSThe study included a total of 183 patients (96 (52.5%) prescribed adalimumab; 87 (47.5%) golimumab), and patients were mostly first line (79.8%). Demographic and clinical characteristics were generally similar between treatment groups. Persistence rates within 12 months were 64.6% for adalimumab and 64.4% for golimumab (p=0.681). Overall, 20.2% switched to other therapy within 1 year, with 8.2% golimumab and 12.0% adalimumab switching to another biologic. Of patients prescribed adalimumab, 14.6% had ≥1 dose change, mainly dose escalations. In the 12 months post treatment initiation, 8.2% of patients underwent colectomy, with no significant difference in colectomy-free survival by treatment, p=0.73.This study provides evidence of clinical outcomes and real-world persistence for adalimumab and golimumab in UC. The persistence rates of both therapies were above 64.0% at 12 months following treatment initiation. In addition, the 1-year colectomy-free survival was relatively similar between the two treatments.CONCLUSIONThis study provides evidence of clinical outcomes and real-world persistence for adalimumab and golimumab in UC. The persistence rates of both therapies were above 64.0% at 12 months following treatment initiation. In addition, the 1-year colectomy-free survival was relatively similar between the two treatments. |
| Author | Roberts, Jenna Green, Chloe Hoque, Sami Puenpatom, Amy Boccaletti, Simona Black, Christopher M Rajkovic, Ivana Milligan, Gary |
| AuthorAffiliation | 2 Center for Observational and Real-World Evidence , Merck & Co., Inc , Kenilworth , New Jersey , USA 3 Health Economics and Outcome Research , MSD Ltd , Hertfordshire , UK 4 Observational Research Department , Adelphi Real World , Bollington , UK 1 Department of Gastroenterology , Barts Health NHS Trust , London , UK |
| AuthorAffiliation_xml | – name: 1 Department of Gastroenterology , Barts Health NHS Trust , London , UK – name: 4 Observational Research Department , Adelphi Real World , Bollington , UK – name: 2 Center for Observational and Real-World Evidence , Merck & Co., Inc , Kenilworth , New Jersey , USA – name: 3 Health Economics and Outcome Research , MSD Ltd , Hertfordshire , UK |
| Author_xml | – sequence: 1 givenname: Sami surname: Hoque fullname: Hoque, Sami organization: Department of Gastroenterology, Barts Health NHS Trust, London, UK – sequence: 2 givenname: Amy surname: Puenpatom fullname: Puenpatom, Amy organization: Center for Observational and Real-World Evidence, Merck & Co., Inc, Kenilworth, New Jersey, USA – sequence: 3 givenname: Simona surname: Boccaletti fullname: Boccaletti, Simona organization: Health Economics and Outcome Research, MSD Ltd, Hertfordshire, UK – sequence: 4 givenname: Chloe surname: Green fullname: Green, Chloe organization: Health Economics and Outcome Research, MSD Ltd, Hertfordshire, UK – sequence: 5 givenname: Christopher M surname: Black fullname: Black, Christopher M organization: Center for Observational and Real-World Evidence, Merck & Co., Inc, Kenilworth, New Jersey, USA – sequence: 6 givenname: Jenna surname: Roberts fullname: Roberts, Jenna organization: Observational Research Department, Adelphi Real World, Bollington, UK – sequence: 7 givenname: Ivana surname: Rajkovic fullname: Rajkovic, Ivana email: Ivana.rajkovic@adelphigroup.com organization: Observational Research Department, Adelphi Real World, Bollington, UK – sequence: 8 givenname: Gary surname: Milligan fullname: Milligan, Gary organization: Observational Research Department, Adelphi Real World, Bollington, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33199269$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk1v1DAQhiNUREvpL0BClrhwSeuPOLY5IFUVHxWVuLRny3EmW6-SeLGdLfsP-Nk47LK0PUBPtsfv886Mxy-Lg9GPUBSvCT4lhNVnzbBcmJhKiikuMcaVqJ8VRxTzqqyEqA7u7Q-LkxiXWUM4qyiVL4pDxohStFZHxc_rACYNMCa0ghBdTDBaQGZskfU92OSHTdkFAOSnZP0AEbkRrUxyGYnozqVbNPUWQo6sYWZcchEFsODWblygRY4M02Aa5AMyrdmd3iODbr4i-JGzujnlq-J5Z_oIJ7v1uLj59PH64kt59e3z5cX5VdlwIVMpJUhJFO9wI6RSrGsoJYYJ3oHCpiNCEU5IizlTNTEWsBDCUKiskaaxqmXHxeXWt_VmqVfBDSZstDdO_w74sNAmJGd70Jh3bStN3VpeVyon7qCignPMeMtbZrNXtfWaxpXZ3Jm-3xsSrOc56d2c9DwnvZ1Txj5ssdXUDNDa_JLB9A9qeXgzulu98GstaoElZ9ng3c4g-O8TZPvBRQt9b0bwU9S0qglTUmGapW8fSZd-CmN-4VmFFZM1J1n15n5F-1L-_JMsYFuBDT7GAN0TG1WPKOtS_ih-bsv1_2FPt2y-fGKys7_Avsl_Eb8AGdMG6w |
| CitedBy_id | crossref_primary_10_1080_03007995_2023_2194782 crossref_primary_10_1007_s12325_024_02942_6 crossref_primary_10_1007_s40264_025_01519_8 crossref_primary_10_1080_00365521_2021_2014950 crossref_primary_10_1111_apt_18006 crossref_primary_10_18553_jmcp_2024_30_9_1026 crossref_primary_10_1093_jcag_gwae040 crossref_primary_10_1097_MEG_0000000000002443 crossref_primary_10_1016_j_yjpso_2023_100084 crossref_primary_10_1186_s12876_023_02640_7 crossref_primary_10_1016_j_dld_2021_08_020 crossref_primary_10_7759_cureus_37609 |
| Cites_doi | 10.1093/crocol/otz022 10.1016/S0140-6736(12)60150-0 10.1093/gastro/goz004 10.1111/apt.12145 10.2147/DDDT.S33197 10.1016/j.clinthera.2018.07.013 10.15403/jgld.2014.1121.263.trs 10.1159/000496739 10.1080/03007995.2019.1631058 10.1371/journal.pone.0149692 10.1080/03007995.2019.1579557 10.1016/j.mayocp.2014.07.002 10.1016/S0140-6736(16)32126-2 10.1093/jcag/gwy019 10.1016/j.crohns.2012.03.016 10.1093/ecco-jcc/jjx009 10.1093/ecco-jcc/jjw019.078 10.1080/00365521.2020.1713210 10.1097/MIB.0000000000001144 10.1097/MD.0000000000011897 10.1007/s10620-016-4398-5 10.1111/jcpt.12830 10.1177/1756283X10382816 10.3748/wjg.v24.i47.5322 10.1007/s12325-018-0759-0 10.1093/ibd/izz001 10.1177/1756283X17750355 10.1053/j.gastro.2013.06.010 10.14309/01.ajg.0000578168.58762.d8 10.12688/f1000research.15159.1 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020 |
| DBID | 9YT ACMMV AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1136/bmjgast-2020-000476 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central BMJ Journals ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition BMJ Journals Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2054-4774 |
| ExternalDocumentID | oai_doaj_org_article_05fdd8a6dc56498e8fe42755035d5d3c 10.1136/bmjgast-2020-000476 PMC7670853 33199269 10_1136_bmjgast_2020_000476 bmjgast |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom--UK United States--US |
| GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US |
| GrantInformation_xml | – fundername: Merck Sharp and Dohme grantid: NO: 7139 funderid: http://dx.doi.org/10.13039/100009947 – fundername: ; grantid: NO: 7139 |
| GroupedDBID | 53G 5VS 7X7 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV BENPR BPHCQ BTHHO CCPQU DIK FYUFA GROUPED_DOAJ HMCUK HYE KQ8 M48 M~E OK1 PGMZT PHGZT PQQKQ RMJ RPM UKHRP AAYXX ADRAZ CITATION PHGZM PJZUB PPXIY PUEGO NPM 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-b578t-88e88195f0b78993fb221a375fe90af1791511d053961ace0777a2e4ca8abc9d3 |
| IEDL.DBID | 9YT |
| ISSN | 2054-4774 |
| IngestDate | Wed Aug 27 01:31:32 EDT 2025 Wed Aug 20 00:21:32 EDT 2025 Tue Sep 30 15:32:02 EDT 2025 Wed Oct 01 14:45:55 EDT 2025 Fri Jul 25 22:18:30 EDT 2025 Thu Apr 03 06:57:17 EDT 2025 Wed Oct 01 05:41:50 EDT 2025 Thu Apr 24 23:06:21 EDT 2025 Thu Apr 24 22:51:35 EDT 2025 Thu Apr 24 22:50:25 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | colorectal surgery inflammatory diseases ulcerative colitis antibody targeted therapy |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. cc-by-nc |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b578t-88e88195f0b78993fb221a375fe90af1791511d053961ace0777a2e4ca8abc9d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://dx.doi.org/10.1136/bmjgast-2020-000476 |
| PMID | 33199269 |
| PQID | 2460938651 |
| PQPubID | 2040973 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_05fdd8a6dc56498e8fe42755035d5d3c unpaywall_primary_10_1136_bmjgast_2020_000476 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7670853 proquest_miscellaneous_2461398902 proquest_journals_2460938651 pubmed_primary_33199269 crossref_primary_10_1136_bmjgast_2020_000476 crossref_citationtrail_10_1136_bmjgast_2020_000476 bmj_primary_10_1136_bmjgast_2020_000476 bmj_journals_10_1136_bmjgast_2020_000476 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-11-16 |
| PublicationDateYYYYMMDD | 2020-11-16 |
| PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationTitle | BMJ open gastroenterology |
| PublicationTitleAbbrev | BMJ Open Gastro BMJ Open Gastroenterol |
| PublicationTitleAlternate | BMJ Open Gastroenterol |
| PublicationYear | 2020 |
| Publisher | BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Wehkamp, Stange (R9) 2018 Lim, Panaccione, Seow (R10) 2011; 4 Bressler, Williamson, Sattin (R17) 2018; 1 Brady, Stott-Miller, Mu (R15) 2018; 40 Black, Yu, McCann (R33) 2016; 11 Antonelli, Villanacci, Bassotti (R4) 2018; 24 Angelison, Almer, Davidsdottir (R26) 2020; 55 Ordás, Eckmann, Talamini (R3) 2012; 380 Taxonera, Rodríguez, Bertoletti (R18) 2017; 23 Gemayel, Rizzello, Atanasov (R31) 2019; 35 Armuzzi, Pugliese, Nardone (R29) 2013; 7 Vermeire, Gils, Accossato (R11) 2018; 11 Sandborn, Feagan, Marano (R23) 2014; 146 McDermott, Murphy, Keegan (R14) 2013; 7 Chen, Hartzema, Xiao (R13) 2019; 25 Ungaro, Mehandru, Allen (R2) 2017; 389 Maniadakis, Toth, Schiff (R12) 2018; 35 (R25) 2016; 10 Harbord, Eliakim, Bettenworth (R7) 2017; 11 Wong, Roth, Feuerstein (R28) 2019; 7 Feuerstein, Cheifetz (R5) 2014; 89 Otsuka, Ooi, Tobimatsu (R21) 2018; 64 Comerford E, Smith (R16) 2019; 114 Tursi, Allegretta, Buccianti (R20) 2017; 26 Sandborn, Colombel, D'Haens (R24) 2013; 37 Patel, Latremouille-Viau, Burne (R27) 2019; 1 Danese, Allez, van Bodegraven (R8) 2019; 37 Tursi, Elisei, Faggiani (R30) 2018; 97 Taxonera, Iglesias, Muñoz (R19) 2017; 62 Khan, Rupniewska, Neighbors (R32) 2019; 44 Taxonera, Iborra, Bosca-Watts (R34) 2019; 35 Brady, Stott-Miller, Mu 2018; 40 Taxonera, Iborra, Bosca-Watts 2019; 35 Danese, Allez, van Bodegraven 2019; 37 Lim, Panaccione, Seow 2011; 4 Comerford E, Smith 2019; 114 Tursi, Elisei, Faggiani 2018; 97 Sandborn, Feagan, Marano 2014; 146 2016; 10 Feuerstein, Cheifetz 2014; 89 Wehkamp, Stange 2018 Armuzzi, Pugliese, Nardone 2013; 7 Black, Yu, McCann 2016; 11 Patel, Latremouille-Viau, Burne 2019; 1 Ungaro, Mehandru, Allen 2017; 389 Antonelli, Villanacci, Bassotti 2018; 24 McDermott, Murphy, Keegan 2013; 7 Tursi, Allegretta, Buccianti 2017; 26 Sandborn, Colombel, D'Haens 2013; 37 Angelison, Almer, Davidsdottir 2020; 55 Harbord, Eliakim, Bettenworth 2017; 11 Vermeire, Gils, Accossato 2018; 11 Taxonera, Iglesias, Muñoz 2017; 62 Wong, Roth, Feuerstein 2019; 7 Otsuka, Ooi, Tobimatsu 2018; 64 Ordás, Eckmann, Talamini 2012; 380 Gemayel, Rizzello, Atanasov 2019; 35 Khan, Rupniewska, Neighbors 2019; 44 Bressler, Williamson, Sattin 2018; 1 Taxonera, Rodríguez, Bertoletti 2017; 23 Maniadakis, Toth, Schiff 2018; 35 Chen, Hartzema, Xiao 2019; 25 2025073013241296000_7.1.e000476.1 2025073013241296000_7.1.e000476.3 Tursi (2025073013241296000_7.1.e000476.30) 2018; 97 2025073013241296000_7.1.e000476.2 2025073013241296000_7.1.e000476.5 Comerford E (2025073013241296000_7.1.e000476.16) 2019; 114 2025073013241296000_7.1.e000476.6 2025073013241296000_7.1.e000476.9 Wong (2025073013241296000_7.1.e000476.28) 2019; 7 Maniadakis (2025073013241296000_7.1.e000476.12) 2018; 35 Taxonera (2025073013241296000_7.1.e000476.19) 2017; 62 Gemayel (2025073013241296000_7.1.e000476.31) 2019; 35 Angelison (2025073013241296000_7.1.e000476.26) 2020; 55 2025073013241296000_7.1.e000476.23 2025073013241296000_7.1.e000476.22 2025073013241296000_7.1.e000476.24 Khan (2025073013241296000_7.1.e000476.32) 2019; 44 Vermeire (2025073013241296000_7.1.e000476.11) 2018; 11 Antonelli (2025073013241296000_7.1.e000476.4) 2018; 24 Patel (2025073013241296000_7.1.e000476.27) 2019; 1 Taxonera (2025073013241296000_7.1.e000476.18) 2017; 23 (2025073013241296000_7.1.e000476.25) 2016; 10 Black (2025073013241296000_7.1.e000476.33) 2016; 11 Danese (2025073013241296000_7.1.e000476.8) 2019; 37 2025073013241296000_7.1.e000476.10 Armuzzi (2025073013241296000_7.1.e000476.29) 2013; 7 Taxonera (2025073013241296000_7.1.e000476.34) 2019; 35 2025073013241296000_7.1.e000476.14 Brady (2025073013241296000_7.1.e000476.15) 2018; 40 Tursi (2025073013241296000_7.1.e000476.20) 2017; 26 Otsuka (2025073013241296000_7.1.e000476.21) 2018; 64 Chen (2025073013241296000_7.1.e000476.13) 2019; 25 Harbord (2025073013241296000_7.1.e000476.7) 2017; 11 Bressler (2025073013241296000_7.1.e000476.17) 2018; 1 |
| References_xml | – volume: 1 start-page: 360 year: 2019 ident: R27 article-title: Comparison of real-world treatment outcomes with Vedolizumab versus infliximab in Biologic-Naive patients with inflammatory bowel disease publication-title: Crohns Colitis 360 doi: 10.1093/crocol/otz022 – volume: 380 start-page: 1606 year: 2012 ident: R3 article-title: Ulcerative colitis publication-title: Lancet doi: 10.1016/S0140-6736(12)60150-0 – volume: 7 start-page: 77 year: 2019 ident: R28 article-title: Surgery in the age of biologics publication-title: Gastroenterol Rep doi: 10.1093/gastro/goz004 – volume: 37 start-page: 204 year: 2013 ident: R24 article-title: One-Year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ultra 2 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12145 – volume: 7 start-page: 289 year: 2013 ident: R29 article-title: Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S33197 – volume: 40 start-page: 1509 year: 2018 ident: R15 article-title: Treatment patterns and sequencing in patients with inflammatory bowel disease publication-title: Clin Ther doi: 10.1016/j.clinthera.2018.07.013 – volume: 26 start-page: 239 year: 2017 ident: R20 article-title: Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers publication-title: J Gastrointestin Liver Dis doi: 10.15403/jgld.2014.1121.263.trs – volume: 64 start-page: E140 year: 2018 ident: R21 article-title: Short-Term and long-term outcomes of infliximab and tacrolimus treatment for moderate to severe ulcerative colitis: retrospective observational study publication-title: Kobe J Med Sci – start-page: 7 year: 2018 ident: R9 article-title: Recent advances and emerging therapies in the non-surgical management of ulcerative colitis publication-title: F1000Res – volume: 114 start-page: pS7 year: 2019 ident: R16 article-title: Treatment patterns of biologic therapies used to treat ulcerative colitis: a retrospective database analysis in the United States publication-title: Am J Gastroenterol – volume: 37 start-page: 266 year: 2019 ident: R8 article-title: Unmet medical needs in ulcerative colitis: an expert group consensus publication-title: Dig Dis doi: 10.1159/000496739 – volume: 35 start-page: 1911 year: 2019 ident: R31 article-title: Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1631058 – volume: 11 year: 2016 ident: R33 article-title: Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data publication-title: PLoS One doi: 10.1371/journal.pone.0149692 – volume: 35 start-page: 1297 year: 2019 ident: R34 article-title: Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1579557 – volume: 89 start-page: 1553 year: 2014 ident: R5 article-title: Ulcerative colitis: epidemiology, diagnosis, and management publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2014.07.002 – volume: 389 start-page: 1756 year: 2017 ident: R2 article-title: Ulcerative colitis publication-title: Lancet doi: 10.1016/S0140-6736(16)32126-2 – volume: 1 start-page: 129 year: 2018 ident: R17 article-title: Real world effectiveness of golimumab therapy in ulcerative colitis regardless of prior TNF exposure publication-title: J Can Assoc Gastroenterol doi: 10.1093/jcag/gwy019 – volume: 7 start-page: 150 year: 2013 ident: R14 article-title: Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2012.03.016 – volume: 11 start-page: 769 year: 2017 ident: R7 article-title: Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjx009 – volume: 10 start-page: S57 year: 2016 ident: R25 article-title: Efficacy and safety of golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom: results from the GO-COLITIS study publication-title: Journal of Crohn's and Colitis doi: 10.1093/ecco-jcc/jjw019.078 – volume: 55 start-page: 154 year: 2020 ident: R26 article-title: Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study publication-title: Scand J Gastroenterol doi: 10.1080/00365521.2020.1713210 – volume: 23 start-page: 1394 year: 2017 ident: R18 article-title: Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000001144 – volume: 97 year: 2018 ident: R30 article-title: Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: a real-life multicenter, observational study in primary inflammatory bowel disease centers publication-title: Medicine doi: 10.1097/MD.0000000000011897 – volume: 62 start-page: 481 year: 2017 ident: R19 article-title: Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation publication-title: Dig Dis Sci doi: 10.1007/s10620-016-4398-5 – volume: 44 start-page: 495 year: 2019 ident: R32 article-title: Real-World evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.12830 – volume: 4 start-page: 145 year: 2011 ident: R10 article-title: Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease publication-title: Therap Adv Gastroenterol doi: 10.1177/1756283X10382816 – volume: 24 start-page: 5322 year: 2018 ident: R4 article-title: Novel oral-targeted therapies for mucosal healing in ulcerative colitis publication-title: World J Gastroenterol doi: 10.3748/wjg.v24.i47.5322 – volume: 35 start-page: 1333 year: 2018 ident: R12 article-title: A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences publication-title: Adv Ther doi: 10.1007/s12325-018-0759-0 – volume: 25 start-page: 1417 year: 2019 ident: R13 article-title: Real-World pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy publication-title: Inflamm Bowel Dis doi: 10.1093/ibd/izz001 – volume: 11 year: 2018 ident: R11 article-title: Immunogenicity of biologics in inflammatory bowel disease publication-title: Therap Adv Gastroenterol doi: 10.1177/1756283X17750355 – volume: 146 start-page: 96 year: 2014 ident: R23 article-title: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.06.010 – volume: 62 start-page: 481 year: 2017 article-title: Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation publication-title: Dig Dis Sci doi: 10.1007/s10620-016-4398-5 – volume: 40 start-page: 1509 year: 2018 article-title: Treatment patterns and sequencing in patients with inflammatory bowel disease publication-title: Clin Ther doi: 10.1016/j.clinthera.2018.07.013 – volume: 37 start-page: 204 year: 2013 article-title: One-Year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ultra 2 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12145 – start-page: 7 year: 2018 article-title: Recent advances and emerging therapies in the non-surgical management of ulcerative colitis publication-title: F1000Res – volume: 7 start-page: 150 year: 2013 article-title: Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2012.03.016 – volume: 44 start-page: 495 year: 2019 article-title: Real-World evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.12830 – volume: 146 start-page: 96 year: 2014 article-title: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.06.010 – volume: 37 start-page: 266 year: 2019 article-title: Unmet medical needs in ulcerative colitis: an expert group consensus publication-title: Dig Dis doi: 10.1159/000496739 – volume: 55 start-page: 154 year: 2020 article-title: Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study publication-title: Scand J Gastroenterol doi: 10.1080/00365521.2020.1713210 – volume: 7 start-page: 77 year: 2019 article-title: Surgery in the age of biologics publication-title: Gastroenterol Rep doi: 10.1093/gastro/goz004 – volume: 11 year: 2018 article-title: Immunogenicity of biologics in inflammatory bowel disease publication-title: Therap Adv Gastroenterol doi: 10.1177/1756283X17750355 – volume: 4 start-page: 145 year: 2011 article-title: Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease publication-title: Therap Adv Gastroenterol doi: 10.1177/1756283X10382816 – volume: 380 start-page: 1606 year: 2012 article-title: Ulcerative colitis publication-title: Lancet doi: 10.1016/S0140-6736(12)60150-0 – volume: 23 start-page: 1394 year: 2017 article-title: Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000001144 – volume: 1 start-page: 129 year: 2018 article-title: Real world effectiveness of golimumab therapy in ulcerative colitis regardless of prior TNF exposure publication-title: J Can Assoc Gastroenterol doi: 10.1093/jcag/gwy019 – volume: 114 start-page: pS7 year: 2019 article-title: Treatment patterns of biologic therapies used to treat ulcerative colitis: a retrospective database analysis in the United States publication-title: Am J Gastroenterol – volume: 10 start-page: S57 year: 2016 article-title: Efficacy and safety of golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom: results from the GO-COLITIS study publication-title: Journal of Crohn's and Colitis doi: 10.1093/ecco-jcc/jjw019.078 – volume: 11 year: 2016 article-title: Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data publication-title: PLoS One doi: 10.1371/journal.pone.0149692 – volume: 26 start-page: 239 year: 2017 article-title: Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers publication-title: J Gastrointestin Liver Dis doi: 10.15403/jgld.2014.1121.263.trs – volume: 24 start-page: 5322 year: 2018 article-title: Novel oral-targeted therapies for mucosal healing in ulcerative colitis publication-title: World J Gastroenterol doi: 10.3748/wjg.v24.i47.5322 – volume: 64 start-page: E140 year: 2018 article-title: Short-Term and long-term outcomes of infliximab and tacrolimus treatment for moderate to severe ulcerative colitis: retrospective observational study publication-title: Kobe J Med Sci – volume: 97 year: 2018 article-title: Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: a real-life multicenter, observational study in primary inflammatory bowel disease centers publication-title: Medicine doi: 10.1097/MD.0000000000011897 – volume: 389 start-page: 1756 year: 2017 article-title: Ulcerative colitis publication-title: Lancet doi: 10.1016/S0140-6736(16)32126-2 – volume: 35 start-page: 1333 year: 2018 article-title: A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences publication-title: Adv Ther doi: 10.1007/s12325-018-0759-0 – volume: 1 start-page: 360 year: 2019 article-title: Comparison of real-world treatment outcomes with Vedolizumab versus infliximab in Biologic-Naive patients with inflammatory bowel disease publication-title: Crohns Colitis 360 doi: 10.1093/crocol/otz022 – volume: 7 start-page: 289 year: 2013 article-title: Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S33197 – volume: 89 start-page: 1553 year: 2014 article-title: Ulcerative colitis: epidemiology, diagnosis, and management publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2014.07.002 – volume: 35 start-page: 1297 year: 2019 article-title: Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1579557 – volume: 25 start-page: 1417 year: 2019 article-title: Real-World pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy publication-title: Inflamm Bowel Dis doi: 10.1093/ibd/izz001 – volume: 35 start-page: 1911 year: 2019 article-title: Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1631058 – volume: 11 start-page: 769 year: 2017 article-title: Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjx009 – volume: 62 start-page: 481 year: 2017 ident: 2025073013241296000_7.1.e000476.19 article-title: Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation publication-title: Dig Dis Sci doi: 10.1007/s10620-016-4398-5 – ident: 2025073013241296000_7.1.e000476.22 – volume: 11 year: 2016 ident: 2025073013241296000_7.1.e000476.33 article-title: Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data publication-title: PLoS One doi: 10.1371/journal.pone.0149692 – ident: 2025073013241296000_7.1.e000476.5 doi: 10.1016/j.mayocp.2014.07.002 – volume: 10 start-page: S57 year: 2016 ident: 2025073013241296000_7.1.e000476.25 article-title: Efficacy and safety of golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom: results from the GO-COLITIS study publication-title: Journal of Crohn's and Colitis doi: 10.1093/ecco-jcc/jjw019.078 – volume: 55 start-page: 154 year: 2020 ident: 2025073013241296000_7.1.e000476.26 article-title: Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study publication-title: Scand J Gastroenterol doi: 10.1080/00365521.2020.1713210 – volume: 26 start-page: 239 year: 2017 ident: 2025073013241296000_7.1.e000476.20 article-title: Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers publication-title: J Gastrointestin Liver Dis doi: 10.15403/jgld.2014.1121.263.trs – volume: 11 year: 2018 ident: 2025073013241296000_7.1.e000476.11 article-title: Immunogenicity of biologics in inflammatory bowel disease publication-title: Therap Adv Gastroenterol doi: 10.1177/1756283X17750355 – ident: 2025073013241296000_7.1.e000476.24 doi: 10.1111/apt.12145 – volume: 7 start-page: 77 year: 2019 ident: 2025073013241296000_7.1.e000476.28 article-title: Surgery in the age of biologics publication-title: Gastroenterol Rep doi: 10.1093/gastro/goz004 – volume: 35 start-page: 1333 year: 2018 ident: 2025073013241296000_7.1.e000476.12 article-title: A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences publication-title: Adv Ther doi: 10.1007/s12325-018-0759-0 – volume: 37 start-page: 266 year: 2019 ident: 2025073013241296000_7.1.e000476.8 article-title: Unmet medical needs in ulcerative colitis: an expert group consensus publication-title: Dig Dis doi: 10.1159/000496739 – volume: 114 start-page: pS7 year: 2019 ident: 2025073013241296000_7.1.e000476.16 article-title: Treatment patterns of biologic therapies used to treat ulcerative colitis: a retrospective database analysis in the United States publication-title: Am J Gastroenterol doi: 10.14309/01.ajg.0000578168.58762.d8 – ident: 2025073013241296000_7.1.e000476.2 doi: 10.1016/S0140-6736(16)32126-2 – volume: 1 start-page: 129 year: 2018 ident: 2025073013241296000_7.1.e000476.17 article-title: Real world effectiveness of golimumab therapy in ulcerative colitis regardless of prior TNF exposure publication-title: J Can Assoc Gastroenterol doi: 10.1093/jcag/gwy019 – volume: 97 year: 2018 ident: 2025073013241296000_7.1.e000476.30 article-title: Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: a real-life multicenter, observational study in primary inflammatory bowel disease centers publication-title: Medicine doi: 10.1097/MD.0000000000011897 – ident: 2025073013241296000_7.1.e000476.23 doi: 10.1053/j.gastro.2013.06.010 – ident: 2025073013241296000_7.1.e000476.10 doi: 10.1177/1756283X10382816 – ident: 2025073013241296000_7.1.e000476.14 doi: 10.1016/j.crohns.2012.03.016 – volume: 1 start-page: 360 year: 2019 ident: 2025073013241296000_7.1.e000476.27 article-title: Comparison of real-world treatment outcomes with Vedolizumab versus infliximab in Biologic-Naive patients with inflammatory bowel disease publication-title: Crohns Colitis 360 – volume: 44 start-page: 495 year: 2019 ident: 2025073013241296000_7.1.e000476.32 article-title: Real-World evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review publication-title: J Clin Pharm Ther – ident: 2025073013241296000_7.1.e000476.1 – volume: 35 start-page: 1911 year: 2019 ident: 2025073013241296000_7.1.e000476.31 article-title: Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1631058 – volume: 40 start-page: 1509 year: 2018 ident: 2025073013241296000_7.1.e000476.15 article-title: Treatment patterns and sequencing in patients with inflammatory bowel disease publication-title: Clin Ther doi: 10.1016/j.clinthera.2018.07.013 – ident: 2025073013241296000_7.1.e000476.6 – volume: 23 start-page: 1394 year: 2017 ident: 2025073013241296000_7.1.e000476.18 article-title: Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000001144 – volume: 11 start-page: 769 year: 2017 ident: 2025073013241296000_7.1.e000476.7 article-title: Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjx009 – volume: 25 start-page: 1417 year: 2019 ident: 2025073013241296000_7.1.e000476.13 article-title: Real-World pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy publication-title: Inflamm Bowel Dis doi: 10.1093/ibd/izz001 – ident: 2025073013241296000_7.1.e000476.3 doi: 10.1016/S0140-6736(12)60150-0 – ident: 2025073013241296000_7.1.e000476.9 doi: 10.12688/f1000research.15159.1 – volume: 64 start-page: E140 year: 2018 ident: 2025073013241296000_7.1.e000476.21 article-title: Short-Term and long-term outcomes of infliximab and tacrolimus treatment for moderate to severe ulcerative colitis: retrospective observational study publication-title: Kobe J Med Sci – volume: 35 start-page: 1297 year: 2019 ident: 2025073013241296000_7.1.e000476.34 article-title: Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis publication-title: Curr Med Res Opin doi: 10.1080/03007995.2019.1579557 – volume: 24 start-page: 5322 year: 2018 ident: 2025073013241296000_7.1.e000476.4 article-title: Novel oral-targeted therapies for mucosal healing in ulcerative colitis publication-title: World J Gastroenterol doi: 10.3748/wjg.v24.i47.5322 – volume: 7 start-page: 289 year: 2013 ident: 2025073013241296000_7.1.e000476.29 article-title: Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S33197 |
| SSID | ssj0001534228 |
| Score | 2.2100704 |
| Snippet | ObjectiveTo examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC)... To examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC) prescribed... Objective To examine real-world treatment persistence, colectomy-free survival and treatment switching patterns in UK patients with ulcerative colitis (UC)... |
| SourceID | doaj unpaywall pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e000476 |
| SubjectTerms | antibody targeted therapy Biological products Clinical medicine Clinical trials Colorectal surgery Immunotherapy Inflammatory Bowel Disease inflammatory diseases Medical records Monoclonal antibodies Patients TNF inhibitors ulcerative colitis Variables |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD8AF8SZQkJGQ4EDUJE7shBsgqgoEp67UWzR-la12k9VuItR_wM9mxsmGXYFKDxzj2HnMfBN_tiefGXtlKlVIWyVxCtLH2F9DXEql49RClepEJ94Gtc9v8mSWfz4rzna2-qKcsEEeeDDcUVJ4a0uQ1hQyr0pXepdnCnm1KGxhhaGvL3ZjO4Op4f9gQdpWo8xQKuSRXl6cw6ZDVGTDr9RBZQRL9zqkoNv_N7L5Z87krb5ZweUPWCx2OqTju-zOyCT5--EN7rEbrrnPbn4d18ofsJ-n2xxyvqJJsU1gxxway00bJuuXl7FfO8fbvkPcuQ2fN3zUWd1wmqDl_cK4QRqc2pD8EccvpJvTLAQ_x5JlvwTN2zUHC-PROw589oW7SUP5IZsdfzr9eBKP-y7EGuO3i0u0Mi2v-UQrHI4Jr7MsBaEoLy0BT4KmSNMshm8lUzAuUUpB5nIDJWhTWfGIHTRt454wLgGQU0kvfO5yqCzkRvpSZ0YmOsNLRewNuqAe42ZThyGJkPXorZq8VQ_eithrqroaRDiurpltPVqbUemcNtxYXN3o7dToWvf4QFCZqpJKdyhA7NYjdut_YTdih1ug_TZBlsukop1Y0Tgvp9MY9LSSA41r-1AHmTstEUfs8YDL6UmEoIxiWUVM7SF271H3zzTz70FYXEmFDFxELJ6wfR1bPP0ftnjGbofQpAxLecgOunXvniPf6_SLENq_AC1tU8s priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELZgkYAL4k1gQUZCggPRJnFiJ1wQIFYrEJy2Um_R-NUtapPSNEL7D_jZeBw3pQJVe4xjJ45nxv48M_lMyCtViYLrKolT4DZ26zXEJRcyTjVUqUxkYrVn-_zOzyb5l2kxDQ63LqRVbudEP1HrVqGP_CTLudt8l7xI369-xnhqFEZXwxEa18mN1EEV1GoxFTsfS8GQ4SqQDaWMn8jljxl0G6cb2fBDtecacaV7y5Jn7_8f5Pw3c_JW36zg8hcsFn8tS6d3yZ2AJ-mHQQHukWumuU9ufgsR8wfk9_k2k5yu0DXWeYxModFUtd5lv7yM7doY2vYbNxKmo_OGBrbVjqKblvYLZQaCcGyDJEjUzZNmjr4IOnMly34JkrZrChrC1TsKdPKVmpFJ-SGZnH4-_3QWh9MXYumseBOXpSkxyGYTKdymjFmZZSkwgdlpCVikNXVgTTsjrngKyiRCCMhMrqAEqSrNHpGjpm3ME0I5gENW3DKbmxwqDbnitpSZ4onM3KMi8saJoA7W09V-Y8J4HaRVo7TqQVoReY1VVwMVx-Ga2VaitQp853jsxuJwo7djoyu94yOqylgVubp9Qbue1cH066SwWpfAtSp4XrlRtSbPhNsZskIXmqmIHG8VbTcEO3WPyMvxtjN9jOdAY9re13H4HQPFEXk86OXYE8Ywr5hXERF7GrvX1f07zfzC04sLLhwOZxGJR92-ylg8PfwZz8htb3SYQcmPydFm3ZvnDs9t5AtvtH8Ady9LFg priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELaWRQIuiDeBBRkJAQcMaR52goQQIFYr0HLaSnuLxrFditKk2zaC_gN-NjOJG6hYVj3WsVNrHp4Zz-Qbxp6WuUqlyUMxAukE2msQmVRajAzkIx3q0JkO7fOrPBonn0_T0z22Kcj0BFyeG9pRP6nxonr182z9DhX-re9I8lrPvk9guUKGR_1X0ko-m58J6ixFGVjfZuMSu4zWKiLJP_YhQP8lcUwoWNSDDr0XkaA75MGJ_vNqNEI4umXGOrT_81zUfystr7b1HNY_oKr-MmOHN9h173_y973A3GR7tr7Frhz7DPtt9utkU3nO53SVtux8ag614WXTXfHP1sItrOVNu0JptUs-rblHZ11yutblbVXaHlCc1hBoEsdz1U7p7oJPcGTWzkDzZsHBgP_1hgMff-F2QF6-w8aHn04-HgnfrUFo1PqVyDKbUVLOhVphEBc7HUUjiBVVs4XgCAYVnTuDSp_LEZQ2VEpBZJMSMtBlbuK7bL9uanufcQmAnph0sUtsArmBpJQu01EpQx3hqwL2AllQbISl6AKZWBaeWwVxq-i5FbDnNHXeQ3dcPDPacLQoPT46temoLl70cli00398IFEZphK2dzfQLCaFPyqKMHXGZCBNmcokR6o6m0QKI8k4NamJy4AdbATtDwmiRIY59W9F4jwZHuNRQfkfqG3TdnPQ36fEcsDu9XI57CSOqQ5Z5gFTWxK7tdXtJ_X0WwdHrqRCvz0OmBhkexdaPNhhnw_ZtU7zqOxSHrD91aK1j9AJXOnHnRb_Bm7BWx0 priority: 102 providerName: Scholars Portal |
| Title | Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience |
| URI | https://bmjopengastro.bmj.com/content/7/1/e000476.full https://www.ncbi.nlm.nih.gov/pubmed/33199269 https://www.proquest.com/docview/2460938651 https://www.proquest.com/docview/2461398902 https://pubmed.ncbi.nlm.nih.gov/PMC7670853 https://bmjopengastro.bmj.com/content/bmjgast/7/1/e000476.full.pdf https://doaj.org/article/05fdd8a6dc56498e8fe42755035d5d3c |
| UnpaywallVersion | publishedVersion |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADZ databaseName: BMJ Open Access Journals customDbUrl: eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: 9YT dateStart: 20140101 isFulltext: true titleUrlDefault: https://journals.bmj.com/ providerName: BMJ Publishing Group Ltd – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: KQ8 dateStart: 20140101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: DIK dateStart: 20140101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: RPM dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: 7X7 dateStart: 20140101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2054-4774 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: BENPR dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2054-4774 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0001534228 issn: 2054-4774 databaseCode: M48 dateStart: 20150201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJsFeEJ9bYFRGQoIHIhI7sRPetmnTBOqEUIvKU3SO7VHUplXbCO0_4M_m7KTZKmDqS6L4I7F8d7nz3flnQt6UuUyFzqMwBmFD1NcQZkKqMNaQxypSkdUe7fNSXAyTT6N0dGuz-mYEP-big5r-vILlCsnJmj3QUuyQPSZZ5jK48u-DG5dKyh2gVYst9J--qEOwdEMLebD-f1mYfydKPqirOVz_gsnklhY6f0QetuYjPW7o_ZjcM9UTcr_fBsifkt-DdeI4nTtP2NKbxBQqTcuZ99BPr0O7MIbO6hUym1nScUVbcNUldV5ZWk9K0-CBuz4O84jib9GMneuBXmHJtJ6CorMFBQ3t00cKdPiZmg44-RkZnp8NTi_C9rCFUKHQrsIsM5mLqdlISVyDcasYi4FLl4wWgXUopmibaZTZXMRQmkhKCcwkJWSgylzz52S3mlXmkFABgIaUsNwmJoFcQ1IKmylWikgxfFVA3iEJilZYloVfh3BRtNQqHLWKhloBeeuazhvkjbtbsjVFi7KFN3enbEzu7vS-67TVN04cq3RNHTS3L0B-LVpJL6LUap2B0GUqkhxn1ZqESVwI8lSnmpcBOVoz2s0UsEREuTt-FSfndVeNku7CN1CZWe3boLnu4sIBOWj4shsJ5y6NWOQBkRscuzHUzZpq_MOjiUsh0ezmAQk73t5mLl5sTZmXZN_Ln8udFEdkd7WozSu05FaqR3bkSPa8FPfI3vFpv_8N7ydnl1--9rx3BK_9JPsDRUdKzA |
| linkProvider | BMJ Publishing Group Ltd |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkBgviDsZA4wEggeiJXFiJ0gIcZs6uu2plfqW-ZbSqU1K02jqP-DX8BvxcS6lAlV72WMdO018Ph-fWz4j9EomLKIq8Vyf08w1-zV3Y8qE6yue-MITXqYs2-cZ7Q3D76NotIN-t9_CQFllqxOtolaFhBj5YRBS43zHNPI_zn-6cGoUZFfbIzRqWPT16tK4bOWH469Gvq-D4Ojb4EvPbU4VcIVB59KNYx1D8ijzBDPOBslEEPicMKi68ngGdJ3GCFEGnAn1udQeY4wHOpQ85kImipj73kA3Q-KFwNXPRmwd04kIMGo15EY-oYdidjHm5dJgMag_4LbcJqZ1Yxu0pwX8z8T9t1Jzr8rnfHXJp9O_tsGju-hOY7_iTzXg7qEdnd9Ht06bDP0D9GvQVq7jOYTiSmuTY54rLAubIpit3GyhNS6qpZl5XeJJjht21xJDWBhXU6lrQnIYA6RL2OhlPYHYBx6bllk14wIXC8wVb369xxwP-1h3zM0P0fBa5PII7eZFrp8gTDk3lhzNSBbqkCeKh5JmsQgk9URgbuWgt0YEabNay9Q6QoSmjbRSkFZaS8tBb6DrvKb-2N4zaCWayoZfHY75mG4f9K4bdKX_-AxQ6boCN7htKBbjtFE1qRdlSsWcKhnRMDGzmukwYMYTJZGKFJEOOmiBtp6C9fJy0MvuslE1kD_iuS4q28f4C5CYdtDjGpfdkxACdcw0cRDbQOzGo25eySc_LJ05o8zY_cRBboftq8zF_vbXeIH2eoPTk_Tk-Kz_FN22CxCqN-kB2l0uKv3M2JJL8dwuYIzOr1tj_AGZpYco |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkAYviDuBAUYCwQNRkzixEySEgFFtFCYeVqlvma-jqE1K22jqP-A38es4di6lAlV72WMdO018Ph-fWz4j9FxmLKEqC_yQU-PDfs39lDLhh4pnoQhEYJRj-zymh8P48ygZ7aDf7bcwtqyy1YlOUatS2hh5L4opON8pTcKeacoivh30381--vYEKZtpbY_TqCEy0KtzcN8Wb48OQNYvoqj_6eTjod-cMOALQOrST1Od2kSSCQQDx4MYEUUhJ8xWYAXcWOpOMEgUADWjIZc6YIzxSMeSp1zITBG47xV0lZGY2HIyNmLr-E5CLLtWQ3QUEtoT0x9nfLEEXEb1x9yO5wRaN7ZEd3LA_8zdf6s2r1XFjK_O-WTy15bYv4luNLYsfl-D7xba0cVttPe1ydbfQb9O2ip2PLNhuYWzzzEvFJalSxdMV76Za43LaglS0As8LnDD9LrANkSMq4nUNTm5HWMJmDDoaD22cRB8Bi3TasoFLueYK978eoM5Hg6w7lic76LhpcjlHtotykI_QJhyDlYdNcTEOuaZ4rGkJhWRpIGI4FYeegUiyJuVu8idU0Ro3kgrt9LKa2l56KXtOqtpQLb3jFqJ5rLhWrdHfky2D3rdDbrQf3ywUOm6Wp5w11DOz_JG7eRBYpRKOVUyoXEGs2p0HDHwSkmiEkWkh_ZboK2nYL3UPPSsuwxqx-aSeKHLyvUB38EmqT10v8Zl9ySE2JpmmnmIbSB241E3rxTj747anFEGPgDxkN9h-yJz8XD7azxFe6Ar8i9Hx4NH6Lpbf7aQk-6j3eW80o_BrFyKJ279YnR62QrjDwMEi2M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+persistence+and+colectomy-free+outcomes+in+patients+with+ulcerative+colitis+receiving+golimumab+or+adalimumab%3A+a+UK+experience&rft.jtitle=BMJ+open+gastroenterology&rft.au=Hoque%2C+Sami&rft.au=Puenpatom%2C+Amy&rft.au=Boccaletti%2C+Simona&rft.au=Green%2C+Chloe&rft.date=2020-11-16&rft.issn=2054-4774&rft.eissn=2054-4774&rft.volume=7&rft.issue=1&rft_id=info:doi/10.1136%2Fbmjgast-2020-000476&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2054-4774&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2054-4774&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2054-4774&client=summon |